Cargando…

Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets

Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Yudong, Li, Xingya, Le, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161202/
https://www.ncbi.nlm.nih.gov/pubmed/30208637
http://dx.doi.org/10.3390/pharmaceutics10030155
_version_ 1783358939460534272
author Shen, Yudong
Li, Xingya
Le, Yuan
author_facet Shen, Yudong
Li, Xingya
Le, Yuan
author_sort Shen, Yudong
collection PubMed
description Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti-solvent precipitation via a high-gravity rotating packed bed. Various factors that affect particle size and size distribution, such as excipients, rotating speed, antisolvent/solvent flow rate, were investigated. Structure, stability and in vitro dissolution of the as-prepared SRL were evaluated. Furthermore, the nanoparticulated SRL tablet formula was screened to control drug release. Importantly, SRL tablets exhibit different dissolution profile by adjusting HPMC (hydroxypropyl methyl cellulose) content, which makes them more suitable for various formulation developments.
format Online
Article
Text
id pubmed-6161202
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61612022018-10-01 Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets Shen, Yudong Li, Xingya Le, Yuan Pharmaceutics Article Nanocrystallization and amorphization have proven to be two effective strategies to improve the bioavailability of water-insoluble drugs. The purpose of our work was to develop a nano-formulated tablet of sirolimus (SRL) for enhanced dissolution. Amorphous SRL nanocomposites were prepared using anti-solvent precipitation via a high-gravity rotating packed bed. Various factors that affect particle size and size distribution, such as excipients, rotating speed, antisolvent/solvent flow rate, were investigated. Structure, stability and in vitro dissolution of the as-prepared SRL were evaluated. Furthermore, the nanoparticulated SRL tablet formula was screened to control drug release. Importantly, SRL tablets exhibit different dissolution profile by adjusting HPMC (hydroxypropyl methyl cellulose) content, which makes them more suitable for various formulation developments. MDPI 2018-09-11 /pmc/articles/PMC6161202/ /pubmed/30208637 http://dx.doi.org/10.3390/pharmaceutics10030155 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shen, Yudong
Li, Xingya
Le, Yuan
Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title_full Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title_fullStr Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title_full_unstemmed Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title_short Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
title_sort amorphous nanoparticulate formulation of sirolimus and its tablets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161202/
https://www.ncbi.nlm.nih.gov/pubmed/30208637
http://dx.doi.org/10.3390/pharmaceutics10030155
work_keys_str_mv AT shenyudong amorphousnanoparticulateformulationofsirolimusanditstablets
AT lixingya amorphousnanoparticulateformulationofsirolimusanditstablets
AT leyuan amorphousnanoparticulateformulationofsirolimusanditstablets